



# XXVIII IFSO World Congress

9-12 September 2025 | Santiago, Chile

## Innovation, Money, Power Is there a Right Balance?

Philip R. Schauer MD, FACS, FASMBS  
Director, Metamor™ Institute  
Professor of Metabolic Surgery,  
Pennington Biomedical Research Center  
[Philip.Schauer@pbrc.edu](mailto:Philip.Schauer@pbrc.edu) @PSchauerMD

# IFSO 2025 Santiago

Combined Therapies, The Dawn of a New Era

[ifso2025.org](https://ifso2025.org)



XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile

# Presenter Disclosures

## Philip R. Schauer MD

- Board Member/Advisory Panel – GI Dynamics; Persona; Keyron, Mediflix
- Consultant – Ethicon, Medtronic, Keyron, Novo Nordisk, Lilly, Heron, Regeneron
- Research Support – Ethicon, NIH, Medtronic,
- Stock/Shareholder - SEHQC, LLC, Mediflix, MHI LTD
- **Clinical Trials:**
- **STAMPEDE-Diabetes**
- **MS-MACE**
- **ARMMS-Diabetes**
- **SPLENDOR-NASH**
- **SPLENDID-Cancer**



XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile

# Innovation, Money, and Power Is there a Right Balance?

Collaboration with Industry to Advance the Field of Metabolic Surgery



# XXVIII IFSO World Congress

9-12 September 2025  
Santiago, Chile

## Visionary

--	--

## Gold

--	--

## Silver

--	--	--

## General




[ifso2025.org](https://ifso2025.org)



# XXVIII IFSO World Congress

9-12 September 2025  
Santiago, Chile

## Exhibitor

		Allurion			INTUITIVE		
							Medtronic
							mindray
			InBody				

# Industry and Research – Metabolic Surgery



XXVIII IFSO  
World Congress

United States

125



Home Login

## Welcome to the Investigator Portal

This is the place where researchers, surgeons and physicians can submit their research proposals for Investigator Initiated Study (IIS) grant requests. Users may also submit requests for Publication Grants to support development of manuscripts.

Click on the relevant business below to begin the process

<p>Includes the following areas of specialty:</p> <ul style="list-style-type: none"><li>Bariatric</li><li>Biosurgery</li><li>Digital</li><li>Energy</li><li>Endomechanical</li><li>Magnetic Sphincter Augmentation</li><li>Microwave Ablation</li><li>Robotic Bronchoscopy</li><li>Wound Closure and Healing</li></ul> <p>Begin</p>	<p>Includes the following areas of specialty:</p> <ul style="list-style-type: none"><li>Cardiac Electrophysiology</li><li>Stroke</li><li>Breast Augmentation &amp; Reconstruction</li><li>Ear, Nose &amp; Throat</li></ul> <p>Begin</p>	<p>Includes the following areas of specialty:</p> <ul style="list-style-type: none"><li>Knee</li><li>Spine</li><li>Trauma</li><li>Shoulders</li><li>Cranio-Maxillofacial (CMF)</li><li>Digital</li><li>Sports Medicine</li><li>Hip</li><li>Biomaterials</li></ul> <p>Begin</p>
---	---	--

<https://jnmd-iis-portal.idea-point.com/Home.aspx>

## Medtronic

What can we help you find?

Healthcare Professionals Patients & Caregivers Our Company Our Impact

Home > Healthcare Professionals > External Research Program

### EXTERNAL RESEARCH PROGRAM HEALTHCARE PROFESSIONALS

#### OVERVIEW

**Thank you for your interest in working with Medtronic to support medical research.** Medtronic is dedicated to the development of evidence supporting improvements in patient outcomes around the globe. For more information about research areas of interest, please contact us at [erp@medtronic.com](mailto:erp@medtronic.com).

#### EXTERNAL RESEARCH PROGRAMS (ERP)

Medtronic is committed to the External Research Program (ERP) and evaluates each ERP submission for, among other factors, scientific merit, strategic interest, and degree of new scientific and clinical evidence. Medtronic receives many requests for support of ERP proposals and as a result, not all submissions can be supported.

The investigator is responsible for conducting the study and assuring the validity of the study data. The investigator, and/or investigator's institution, also assumes the roles and responsibilities of the study sponsor, including compliance of all regulatory requirements.

Please note that Medtronic is a potential "supporter" of ERP studies but is not the study "sponsor." As a result, Medtronic will not direct the design, conduct, or outcomes of these studies.

#### RELATED PAGES

- Process and Submission
- Guidelines
- Frequently Asked Questions

#### RELATED LINKS

- Grants and Donations

#### REGISTERED MEMBERS

Log in to manage, review, or submit your research proposal.

LOG IN

#### CONTACT INFORMATION

For any questions regarding the External Research Program (ERP), please contact:

External Research Program

<https://www.medtronic.com/us-en/healthcare-professionals/external-research-program.html>

ifso2025.org



XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile

ORIGINAL ARTICLE

# Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes

Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,  
Kathy Wolski, M.P.H., Ali Aminian, M.D., Stacy A. Brethauer, M.D.,  
Sankar D. Navaneethan, M.D., M.P.H., Rishi P. Singh, M.D., Claire E. Pothier, M.P.H.,  
Steven E. Nissen, M.D., and Sangeeta R. Kashyap, M.D.,  
for the STAMPEDE Investigators\*

20 + articles  
>8,000 citations

## CONCLUSIONS

Five-year outcome data showed that, among patients with type 2 diabetes and a BMI of 27 to 43, bariatric surgery plus intensive medical therapy was more effective than intensive medical therapy alone in decreasing, or in some cases resolving, hyperglycemia.

(Funded by Ethicon Endo-Surgery and others; STAMPEDE ClinicalTrials.gov number, NCT00432809.)



# Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)

<https://doi.org/10.2337/dc21-2441> Diabetes Care. 2022 Jul 7;45(7):1574-1583. doi: 10.2337/dc21-2441.

*John P. Kirwan,<sup>1,2</sup> Anita P. Courcoulas,<sup>3</sup>  
David E. Cummings,<sup>4,5</sup>  
Allison B. Goldfine,<sup>6,7</sup>  
Sangeeta R. Kashyap,<sup>1</sup>  
Donald C. Simonson,<sup>7,8</sup>  
David E. Arterburn,<sup>9</sup> William F. Gourash,<sup>3</sup>  
Ashley H. Vernon,<sup>7,8</sup> John M. Jakicic,<sup>10</sup>  
Mary Elizabeth Patti,<sup>6,7</sup>  
Kathy Wolski,<sup>1</sup> and Philip R. Schauer<sup>1,2</sup>*



**XXVIII IFSO  
World Congress**

**9-12 September 2025  
Santiago, Chile**

**Funding.** This research was primarily supported by an investigator-initiated grant from **Ethicon Endo-Surgery and Medtronic** and by in-kind support from **LifeScan and Novo Nordisk.**



JAMA | Original Investigation

# Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes

Anita P. Courcoulas, MD; Mary Elizabeth Patti, MD; Bo Hu, PhD; David E. Arterburn, MD; Donald C. Simonson, MD, ScD; William F. Gourash, PhD; John M. Jakicic, PhD; Ashley H. Vernon, MD; Gerald J. Beck, PhD; Philip R. Schauer, MD; Sangeeta R. Kashyap, MD; Ali Aminian, MD; David E. Cummings, MD; John P. Kirwan, PhD

← Editorial page 643

+ Multimedia

+ Supplemental content

+ NIH, NIDDK

**IMPORTANCE**

Long-term outcomes of bariatric surgery compared with medical management in type 2 diabetes.

**OBJECTIVE**

To compare long-term outcomes of bariatric surgery with medical management in type 2 diabetes.

**Funding.** This research was primarily supported by an investigator-initiated grant from Ethicon Endo-Surgery and Medtronic and by in-kind support from LifeScan and Novo Nordisk.

Largest RCT; Longest follow-up



# Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A<sub>1c</sub>, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study

Sayed Ikramuddin, MD, MHA; Judith Korner, MD, PhD; Wei-Jei Lee, MD, PhD; Avis J. Thomas, MS; John E. Connett, PhD; John P. Bantle, MD; Daniel B. Leslie, MD; Qi Wang, MS; William B. Inabnet III, MD; Robert W. Jeffery, PhD; Keong Chong, MD; Lee-Ming Chuang, MD, PhD; Michael D. Jensen, MD; Adrian Vella, MD; Leaque Ahmed, MD; Kumar Belani, MD; Charles J. Billington, MD

**Funding/Support:** The Diabetes Surgery Study was supported by Medtronic Inc, formerly Covidien, Mansfield, Massachusetts. Medtronic provided funds for University of Minnesota, Mayo Clinic, Columbia University, National Taiwan University Hospital, and Min-Sheng General Hospital, Taoyuan,



XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile



XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile



# Gastric bypass *versus* best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial

Ricardo V. Cohen,<sup>a,\*</sup> Tiago Veiga Pereira,<sup>b,c</sup> Cristina Mamédio Aboud,<sup>a</sup> Tarissa Beatrice Zanata Petry,<sup>a</sup> José Luis Lopes Correa,<sup>a</sup> Carlos Aurélio Schiavon,<sup>d</sup> Carlos Eduardo Pompílio,<sup>a</sup> Fernando Nogueira Quirino Pechy,<sup>a</sup> Ana Carolina Calmon da Costa Silva,<sup>a</sup> Lívia Porto Cunha da Silveira,<sup>a</sup> Pedro Paulo de Paris Caravatto,<sup>a</sup> Helio Halpern,<sup>a</sup> Frederico de Lima Jacy Monteiro,<sup>a</sup> Bruno da Costa Martins,<sup>a</sup> Rogerio Kuga,<sup>a</sup> Thais Mantovani Sarian Palumbo,<sup>a</sup> Allon N. Friedman,<sup>e</sup> and Carel W. le Roux<sup>f,g</sup>

<sup>a</sup>The Center for Obesity and Diabetes, Oswaldo Cruz German Hospital, São Paulo, Brazil

<sup>b</sup>Applied Health Research Centre, St. Michael's Hospital, Toronto, Canada

<sup>c</sup>Department of Health Sciences, University of Leicester, Leicester, United Kingdom

<sup>d</sup>Research Institute HCor, Heart Hospital, São Paulo, Brazil

<sup>e</sup>Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>f</sup>Diabetes Complications Research Centre, UCD Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland

<sup>g</sup>Diabetes Research Centre, Ulster University, Coleraine, United Kingdom

## Summary

**Background** We compared the albuminuria-lowering effects of Roux-en-Y gastric bypass (RYGB) to best medical treatment in patients with diabetic kidney disease and obesity to determine which treatment is better.

**Methods** A 5 year, open-label, single-centre, randomised trial studied patients with diabetic kidney disease and class I obesity after 1:1 randomization to best medical treatment (n = 49) or RYGB (n = 51). The primary outcome was the proportion of patients achieving remission of microalbuminuria after 5 years. Secondary outcomes included

eClinicalMedicine  
2022;53: 101725

Published Online 11  
November 2022

<https://doi.org/10.1016/j.eclim.2022.101725>

**Funding** The study was supported by research grants from **Johnson & Johnson Brasil**, Oswaldo Cruz German Hospital, and by grant 12/YI/B2480 from Science Foundation Ireland (Dr le Roux) and grant 2015-02733 from the



XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile

Randomized Controlled Trial > Ann Intern Med. 2020 Nov 3;173(9):685-693.

doi: 10.7326/M19-3781. Epub 2020 Aug 18.

# Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial

Carlos A Schiavon <sup>1</sup>, Deepak L Bhatt <sup>2</sup>, Dimas Ikeoka <sup>3</sup>, Eliana V Santucci <sup>1</sup>, Renato Nakagawa Santos <sup>1</sup>, Lucas P Damiani <sup>1</sup>, Juliana D Oliveira <sup>1</sup>, Rachel Helena V Machado <sup>1</sup>, Helio Halpern <sup>4</sup>, Frederico L J Monteiro <sup>4</sup>, Patricia M Noujaim <sup>4</sup>, Ricardo V Cohen <sup>5</sup>, Marcio G de Souza <sup>6</sup>, Celso Amodeo <sup>7</sup>, Luiz A Bortolotto <sup>8</sup>, Otavio Berwanger <sup>9</sup>, Alexandre B Cavalcanti <sup>1</sup>, Luciano F Drager <sup>8</sup>

Affiliations + expand

PMID: 32805133 DOI: [10.7326/M19-3781](https://doi.org/10.7326/M19-3781)

**Primary funding source:** Ethicon, represented in Brazil by Johnson & Johnson do Brasil.



# XXVIII IFSO World Congress

9-12 September 2025  
Santiago, Chile



# Top 50 Cited Articles in Metabolic Surgery

Rank	First author	Title	Journal	Year	No. of citations
1	Buchwald, H. [10]	Bariatric surgery: a systematic review and meta-analysis	J. Am. Med. Assoc.	2004	2482
2	Sjöström, L. [11]	Effects of bariatric surgery on mortality in Swedish obese subjects	New Engl. J. Med.	2007	1464
3	Sjöström, L. [12]	Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery	New Engl. J. Med.	2004	1434
4	Cummings, D.E. [34]	Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery	New Engl. J. Med.	2002	1296
5	Pories, W.J. [30]	Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus	Ann. Surg.	1995	1164
6	Adams, T.D. [43]	Long-term mortality after gastric bypass surgery	New Engl. J. Med.	2007	916
7	Schauer, P.R. [26]	Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity	Ann. Surg.	2000	813
8	Maggard, M.A. [44]	Meta-analysis: surgical treatment of obesity	Ann. Intern. Med.	2005	701
9	Christou, N.V. [45]	Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients	Ann. Surg.	2004	656
10	Buchwald, H. [27]	Weight and Type 2 diabetes from bariatric surgery: systematic review and meta-analysis	Ann. J. Med.	2009	639
					602
					584
13	Schauer, P.R. [31]	Effect of laparoscopic Roux-en-Y gastric bypass on Type 2 diabetes mellitus	Ann. Surg.	2003	544
14	Wittgrove, A.C. [25]	Laparoscopic gastric bypass, roux en-Y-500 patients: technique and results, with 3–60 month follow-up	Obes. Surg.	2000	531
15	Grundy, S.M. [46]	Gastrointestinal surgery for severe obesity	Ann. Intern. Med.	1991	509
16	Santry, H.P. [47]	Trends in bariatric surgical procedures	J. Am. Med. Assoc.	2005	500
17	Buchwald, H. [38]	Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH)	New Engl. J. Med.	1990	494
18	Buchwald, H. [39]	Bariatric surgery worldwide 2003	Obes. Surg.	2004	436
19	Cancello, R. [48]	Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss	Diabetes	2005	427
20	DeMaria, E.J. [49]	Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity	Ann. Surg.	2002	391

Many were supported by Industry

# Most Cited Papers in Bariatric Surgery



XXVIII IFSO  
World Congress

9-12 September 2025

Rank	Author	Title	Journal	Year	Citations	Funding
1	Buchwald H.	Bariatric surgery: a systematic review and meta-analysis	JAMA	2004	5486	Ethicon
2	Sjostrom L.	Effects of bariatric surgery on mortality in Swedish obese subjects	NEJM	2007	3629	?
3	Sjostrom L.	Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery	NEJM	2004	3332	?
4	Schauer P	STAMPEDE	NEJM	2012	2726	Ethicon
5	Schauer P	STAMPEDE	NEJM	2017	2184	Ethicon



XXVIII IFSO  
World Congress  
9-12 September 2025  
Santiago, Chile

# Industry and Education – Metabolic Surgery

- Fellowship Training
- Surgical Resident Education
- CME – Post-Graduate
- Surgeons
- Physicians
- Professional Societies – ASMBS, IFSO



# XXVIII IFSO World Congress

9-12 September 2025  
Santiago, Chile



- Home
- Manage Program
- Current Fellows
- Job Board
- Applicants
- Fellowship Directory
- About Us
- Log Out



## ABOUT THE FELLOWSHIP COUNCIL

The Fellowship Council is an association of program directors and specialty societies charged with oversight of fellowship training programs in order to uphold uniformly high standards and produce well trained surgeons.

> 2,000 surgeons over 30 years fellowship trained through Industry Support





XXVIII IFSO  
World Congress

9-12 September 2025  
Santiago, Chile

# Conclusion

Our colleagues in industry have and hopefully will continue to  
  
further support research and education in Metabolic Surgery